scholarly article | Q13442814 |
P356 | DOI | 10.1097/00126334-200404150-00007 |
P698 | PubMed publication ID | 15021314 |
P2093 | author name string | Leonardo Calza | |
Roberto Manfredi | |||
Francesco Chiodo | |||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | nevirapine | Q263713 |
efavirenz | Q422645 | ||
P304 | page(s) | 492-502 | |
P577 | publication date | 2004-04-01 | |
P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
P1476 | title | Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study | |
P478 | volume | 35 |
Q36305444 | A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women |
Q57000612 | Antiretroviral Therapy in the Real World : Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients |
Q26852974 | Antiretroviral medication: an emerging category of prescription drug misuse |
Q81433325 | Antiretroviral-associated Hepatotoxicity |
Q37252113 | Canadian consensus guidelines for the optimal use of etravirine in the treatment of HIV-infected adults |
Q37002481 | Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults |
Q37163343 | Current and future antiretroviral treatment options in paediatric HIV infection |
Q37139458 | EFV/FTC/TDF-associated hepatotoxicity: a case report and review |
Q34143084 | Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth |
Q30240127 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
Q24235724 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals |
Q36723853 | Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? |
Q36787311 | Efavirenz: a review |
Q46879488 | Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia |
Q36276597 | Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials |
Q43179922 | Etravirine in first-line therapy |
Q37322060 | Incidence and risk factors for first line anti retroviral treatment failure among Ugandan children attending an urban HIV clinic |
Q43040351 | Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients |
Q36718901 | Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. |
Q36286145 | Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan |
Q36762436 | Neuropsychiatric side effects of efavirenz therapy |
Q27021762 | Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis |
Q37816389 | Pediatric antiretroviral therapy |
Q46923095 | Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine |
Q51547763 | Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. |
Q44513458 | Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial |
Q43179914 | Role of etravirine in combination antiretroviral therapy |
Q37950517 | Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children |
Search more.